New Legislations on Generics and Biosimilars Brewing in Congress

April/May 2009, Vol 2, No 3 - Industry Trends
Dalia Buffery, MA, ABD
Senior Editorial Director
American Health & Drug Benefits
Cranbury, NJ
Download PDF

March was a busy month for makers of generics and biologics, with several bills being introduced in the 111th Congress proposing new legislations on generics and biosimilars. While these bills are making the rounds in committee reviews, responses from industry stakeholders run the gamut from bipartisan support to partisan rejection, with few surprises.

H.R. 1706, Protecting Access to Generic Drugs Act of 2009, was introduced by Rep. Bobby Rush (D-IL) on March 25, 2009.1 This act proposes to “prohibit brandname drug companies from compensating generic drug companies to delay the entry of a generic drug into the market.”1 This practice is perceived by supporters of the bill as hurting consumers by postponing access to cheaper medications. In this economic climate, compounded by the ever-growing rates of chronic diseases, reports of Americans forgoing medications because of cost issues are common, adding fuel to the fire.2

The flip side is, says Rep. Joe Barton (R-TX), the ranking Republican on the House Energy and Commerce Committee (where the bill is being reviewed), that this legislation “could eliminate the motivation for drug makers to settle drug-patent challenges, causing lengthy litigation that ultimately ‘erodes any benefit to the consumer.’”3 This sentiment is echoed by others in the industry, who suggest that this bill may stunt drug innovation, or that “fewer generic drugs may be developed because of this.”3

Responding to critics, Rep. Rush says “the bill is opposed by both PhRMA and most generic companies. The fact that both innovator and generic companies oppose the bill is striking, because brand-name and generic companies are not supposed to agree on anything.” 4 Furthermore, the bill “does not ban all settlements in drug patent cases,” and it “will save taxpayers, businesses, and consumers tens of billions of dollars.”4

In contrast, H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act—which aims “to provide the licensing of biosimilar and biogeneric biological products”5 and was reintroduced to the new Congress by Rep. Henry Waxman (D-CA) on March 11, 20095—was met by bipartisan support in Congress. It does not offer an extended protection period, which likely led Jim Greenwood, president of the Biotechnology Industry Organization, to say, “the bill seeks to cut prices but instead cuts corners,” adding that “this proposal leads us off the map as we seek an effective, fair, and safe pathway to a biosimilar market.”6

A variation on the Waxman bill—H.R. 1548, Pathway for Biosimilars Act—was reintroduced on March 17, 2009, by Rep. Anna Eshoo (D-CA).7 Eli Lilly offered strong support, saying this pathway “carefully weighs the needs of patients and stakeholder companies. This balance…would assure patients and payers the benefits that come from greater competition, preserve incentives for biotechnology innovation and foster investments that will produce more high-paying jobs in the life sciences.”8 Unlike H.R. 1427, this bill offers a 14-year “data protection period.”8

This legislative focus reflects the push toward healthcare reform, cost-reduction, and increased access promoted by the new administration. Stay tuned.

And while this drama has been playing in the halls of Congress, the US Food and Drug Administration has been, quietly, ap proving a slew of new generics since the start of 2009.

References

1. H.R. 1706: Protecting Consumer Access to Generic Drugs Act of 2009. www.govtrack.us/congress/billtext.xpd?bill=h111-1706. Accessed March 29, 2004.
2. Caryn Rabin R. More Americans skipping necessary prescriptions, survey finds. New York Times. January 23, 2009. www.nytimes.com/2009/01/23/health/23drug.html?_r=1. Accessed March 29, 2009.
3. Hughes DA. Bill to stop deals delaying generic drugs could hurt consumers. Wall Street Journal. March 31, 2009. http://online.wsj.com/article/BT-CO-20090331-720508.html. Accessed March 31, 2009.
4. Statement by the Honorable Bobby L. Rush, Chairman Subcommittee on Commerce, Trade and Consumer Protection. March 31, 2009. http://energycommerce.house.gov/Press_111/20090331/rush_open.pdf. Accessed March 31, 2009.
5. H.R. 1427: Promoting Innovation and Access to Life-Saving Medicine Act. March 11, 2009. www.govtrack.us/congress/bill.xpd?bill=h111-1427. Accessed March 29, 2009.
6. Van Arnum P. Bipartisan bill for biosimilars and biogenerics introduced in the House. March 18, 2009. http://pharmtech.findpharma.com/pharmtech/Ingredients/Bipartisan-Bill-for-Biosimiliars-and-Biogenerics-I/ArticleStandard/Article/detail/587445?contextCategoryId=35097. Accessed March 29, 2009.
7. Open Congress. Text of H.R. 1548 as introduced in House for Pathway for Biosimilar Act. March 17, 2009. www.openaccess.orgbill/111-h1548/text. Accessed March 29, 2009.
8. Pathway for Biosimilars Act protects patients, promotes competition, preserves innovation and creates quality jobs, Lilly says. March 17, 2009.
Related Items
FDA Commissioner Outlines New Plan to Increase Biosimilars by Balancing Innovation and Competition
Eileen Koutnik-Fotopoulos
November 2018 Vol 11, No 8 published on November 30, 2018 in Industry Trends
New Rivals: Integrating Health Benefits to Provide Comprehensive Patient Care
Gary Branning, MBA, Martha Vater
April 2018 Vol 11, No 2 published on April 13, 2018 in Industry Trends
Healthcare Trends for 2018
F. Randy Vogenberg, RPh, PhD, John Santilli, MBA
February 2018 Vol 11, No 1 published on February 16, 2018 in Industry Trends
The Value of Pre–FDA Approval Healthcare Economic Information Exchange Between Payers and Drug Manufacturers
Peter R. Fendt, PharmD, MBA, Brian Ung, PharmD, RPh, F. Randy Vogenberg, RPh, PhD
November 2017 Vol 10, No 8 published on November 21, 2017 in Industry Trends
Emphasize Shared Decision-Making Between Physicians and Patients to Improve Diabetes Outcomes
Gary Branning, MBA, Stacey L. Worthy, Esq, Martha Vater
July 2017 Vol 10, No 5 published on July 24, 2017 in Industry Trends
Last modified: November 10, 2011
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME